F. D. Di Pietro

发表

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

L. Strigari, P. Marchetti, I. Zizzari, 2017, Oncotarget.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

L. Strigari, P. Marchetti, I. Zizzari, 2019, Journal of Translational Medicine.

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

L. Strigari, P. Marchetti, M. Simmaco, 2017, Anticancer research.

Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.

P. Marchetti, F. De Galitiis, D. Abeni, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Merkel Cell Carcinoma

E. Dellambra, C. Failla, L. Fania, 2021, Biomedicines.

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients

P. Marchetti, F. De Galitiis, D. Abeni, 2021, Journal of Cancer Research and Clinical Oncology.

[The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.]

E. Dellambra, P. Marchetti, E. Candi, 2020, Recenti progressi in medicina.

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

P. Ascierto, L. Strigari, P. Marchetti, 2020, Vaccines.

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis

B. Daniele, O. Garrone, D. Ciardiello, 2022, Frontiers in Oncology.

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

C. Ficorella, P. Antonetti, A. Parisi, 2021, Supportive Care in Cancer.

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine

P. Marchetti, I. Paris, M. Simmaco, 2017, European Journal of Clinical Pharmacology.

The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy

P. Marchetti, L. Verna, G. Porzio, 2018, Alcohol and alcoholism.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient

L. Strigari, P. Marchetti, M. Simmaco, 2017, Anti-cancer drugs.

The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy

G. Tortora, P. Marchetti, S. Tomao, 2022, Frontiers in Immunology.

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

D. Mallardo, P. Ascierto, P. Marchetti, 2019, Journal of Translational Medicine.

Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

E. Dellambra, E. Candi, F. Ricci, 2020, Biomedicines.

Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

E. Dellambra, E. Candi, F. Ricci, 2021, Biomedicines.

The role of opioids in cancer response to immunotherapy

P. Marchetti, E. Cortesi, A. Botticelli, 2021, Journal of translational medicine.

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC

A. Ceribelli, P. Marchetti, E. Ruggeri, 2018, AntiCancer Research.

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.

N. Tinari, G. Tortora, C. Ficorella, 2021, Clinical colorectal cancer.

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study

G. Tortora, C. Ficorella, A. Parisi, 2021, Frontiers in Oncology.

M. Filetti, D. Galetta, V. Adamo, 2020, medRxiv.

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

F. Marini, P. Marchetti, L. Putignani, 2020, Journal of Translational Medicine.

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients

P. Marchetti, L. Putignani, F. Del Chierico, 2020, Journal of personalized medicine.

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

D. Mallardo, P. Ascierto, P. Marchetti, 2019, Journal of Translational Medicine.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

L. Strigari, P. Marchetti, I. Zizzari, 2019, Journal of Translational Medicine.

Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer

L. Strigari, P. Marchetti, G. Schinzari, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

F. Marini, P. Marchetti, L. Putignani, 2020, Journal of Translational Medicine.

The role of opioids in cancer response to immunotherapy

P. Marchetti, E. Cortesi, A. Botticelli, 2021, Journal of Translational Medicine.

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma

R. Preissner, G. Gentile, A. Botticelli, 2023, Cancers.

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center

Z. C. di Rocco, S. Verkhovskaia, R. Falcone, 2024, Current oncology.